Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

PURPOSE: To compare clinical outcomes in a cohort of patients with advanced non–small-cell lung cancer (NSCLC) with targetable genomic alterations detected using plasma-based circulating tumor DNA (ctDNA) or tumor-based next-generation sequencing (NGS) assays treated with US Food and Drug Administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Hai T., Lam, Vincent K., Elamin, Yasir Y., Hong, Lingzhi, Colen, Rivka, Elshafeey, Nabil A., Hassan, Islam S. A., Altan, Mehmet, Blumenschein, George R., Rinsurongkawong, Waree, Rivera, Melvin J., Vasquez, Mayra E., Carter, Brett W., Byers, Lauren E., Tsao, Anne S., Gibbons, Don L., Fossella, Frank, Glisson, Bonnie S., Zhang, Jianjun, Heymach, John V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345916/
https://www.ncbi.nlm.nih.gov/pubmed/34377884
http://dx.doi.org/10.1200/PO.20.00532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345916/
https://www.ncbi.nlm.nih.gov/pubmed/34377884
http://dx.doi.org/10.1200/PO.20.00532

Ejemplares similares